Posted by Michael Wonder on 05 Sep 2021
CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC
2 September 2021 - Sugemalimab becomes the world’s first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival in patients with stage III non-small-cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.
CStone Pharmaceuticals today announced that the National Medical Products Administration of China has accepted the new drug application for sugemalimab as a consolidation therapy in patients with unresectable stage III non-small-cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.
It is the eighth NDA/supplemental NDA submitted by CStone.
